Showing results (101-110 of 117) with videos related to
Sort By:
Pageof 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2022
Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain LymphomasJurik A Mutter, Stefan K Alig, Mohammad S Esfahani, et al.JAMA Oncology|April 28, 2017
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 TrialSalah-Eddin Al-Batran, Nils Homann, Claudia Pauligk, et al.The New England Journal of Medicine|January 22, 2025
Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal CancerJens Hoeppner, Thomas Brunner, Claudia Schmoor, et al.The Lancet. Haematology|February 1, 2024
High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trialElisabeth Schorb, Lisa Kristina Isbell, Andrea Kerkhoff, et al.Hemasphere|June 24, 2026
Spatial and multi-omic profiling reveals pericyte-derived CCL19 as a key prognostic factor in CNS lymphomaJulia C Kuehn, Lauritz Miarka, Roman Sankowski, et al.The Lancet. Haematology|May 3, 2016
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trialAndrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski, et al.Blood|December 25, 2015
Targetable genetic features of primary testicular and primary central nervous system lymphomasBjoern Chapuy, Margaretha G M Roemer, Chip Stewart, et al.Journal of Neuro-Oncology|August 29, 2019
Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201Andrew S Chi, Rohinton S Tarapore, Matthew D Hall, et al.The Lancet. Oncology|October 26, 2016
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trialSalah-Eddin Al-Batran, Ralf D Hofheinz, Claudia Pauligk, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2024
ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline GliomaIsabel Arrillaga-Romany, Sharon L Gardner, Yazmin Odia, et al.Pageof 12